|
Willett C. |
The Use of Adverse Outcome Pathways (AOPs) to Support Chemical Safety Decisions Within the Context of Integrated Approaches to Testing and Assessment (IATA). In: Kojima H., Seidle T., Spielmann H. (eds) Alternatives to Animal Testing. Springer, Singapore. (2019) |
|
|
Garcia-Reyero N, Perkins EJ, Gayen K, Shoemaker JE, Antczak P, Burgoon L, Falciani F, Gutsell S, Hodges G, Kienzler A, Knapen D, McBride M, Willett C, J Doyle FJ. |
Chemical Hazard Prediction and Hypothesis Testing Using Quantitative Adverse Outcome Pathways. ALTEX. 2019;36(1):91-102. (2018) |
|
|
Marshall LJ, Austin CP, Casey W, Fitzpatrick SC, Willett C. |
Recommendations toward a human pathway-based approach to disease research. Drug Discov Today. 23(11):1824-1832. (2018) |
|
|
Carusi, A., Davies, M.R., De Grandis, G., Escher, B.I., Hodges, Leung, G.K.M.Y., Whelan, M., Willett, C., and G.T. Ankley. |
Harvesting the Promise of AOPs: an assessment and recommendations. Review. Science of the Total Environment, 628–629: 1542–1556. (2018) |
|
|
Willett K, Fitzpatrick S, Meek B, Westmoreland C. |
Use of Adverse Outcome Pathways in Human Risk Assessment and Toxicology. In: A Systems Biology Approach to Advancing Adverse Outcome Pathways for Risk Assessment, Garcia-Reyero, N. and C. Murphy (Eds.). Springer Publishing Company, New York, NY. Pages 349 – 378. ISBN 978-3-319-66084-4 pp 349-378. (2018) |
|
LaLone CA, Ankley GT, Belanger SE, Embry MR, Hodges G, Knapen D, Munn S, Perkins EJ, Rudd MA, Villeneuve DL, Whelan M, Willett C, Zhang X, Hecker M. |
Advancing the adverse outcome pathway framework-An international horizon scanning approach. Environ Toxicol Chem. 36 (6):1411-1421. (2017) |
|
|
Qu XT, Cheng S-J, Qin Y, Ke Y-H. |
Adverse Outcome Pathways Guide and toxicity test application. China Surfactant Detergent & Cosmetics. 46(8): 473-478. (2016) |
|
|
Langley, G., I. Adcock, F. Busquet, K. Crofton, E. Csernok, C. Giese, T. Heinonen, K. Herrmann, M. Hofmann-Apitius, B. Landesmann, L. Marshall 11, E. McIvor, A. Muotri, F. Noor, K. Schutte, T. Seidle, A. van de Stolpe, H. Van Esch, C. Willett, and G. Woszczek. 2016. |
Towards a 21st century roadmap for biomedical research and drug discovery: Consensus report and recommendations. Drug Discovery Today. 22(2):327-339. (2016) |
|
Langley G, Austin CP, Balapure AK, Birnbaum LS, Bucher JR, Fentem J, Fitzpatrick SC, Fowle JR 3rd, Kavlock RJ, Kitano H, Lidbury BA, Muotri AR, Peng SQ, Sakharov D, Seidle T, Trez T, Tonevitsky A, van de Stolpe A, Whelan M, Willett C. |
Lessons from Toxicology: Developing a 21st-Century Paradigm for Medical Research. Environ Health Perspect. 123(11):A268-72.. (2015) |
|
|
Perkins EJ, Antczak P, Burgoon L, Falciani F, Garcia-Reyero N, Gutsell S, Hodges G, Kienzler A, Knapen D, McBride M and C Willett. |
Adverse Outcome Pathways for Regulatory Applications: examination of four case studies with different degrees of completeness and scientific confidence. Tox. Sci. 148 (1): 14-25. (2015) |
|
|
Willett, C. |
Adverse Outcome Pathways: Development and Use in Toxicology. In: Wexler, P. (Ed.), Encyclopedia of Toxicology, 3rd edition vol 1. Elsevier Inc., Academic Press, pp. 95–99. (2014) |
|
|
Willett C, Caverly Rae J, Goyak KO, Landesmann B, Minsavage G, Westmoreland C. |
Pathway-based toxicity: history, current approaches and liver fibrosis and steatosis as prototypes. ALTEX. 2014;31(4):407-21. doi: 10.14573/altex.1401283. (2014) |
|
|
Willett C, Caverly Rae J, Goyak KO, Minsavage G, Westmoreland C, Andersen M, Avigan M, Duché D, Harris G, Hartung T, Jaeschke H, Kleensang A, Landesmann B, Martos S, Matevia M, Toole C, Rowan A, Schultz T, Seed J, Senior J, Shah I, Subramanian K, Vinken M, Watkins P. |
Building shared experience to advance practical application of pathway-based toxicology: liver toxicity mode-of-action. ALTEX. 2014;31(4):500-19. doi: 10.14573/altex.1401281. (2014) |